Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Director · Chief Executive Officer | March 11, 2025 | March 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardiff Oncology, Inc.
Report date March 11, 2025 · Filed March 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.58 · Expires 2035-03-11 | Direct | 2,925,098 |
Reported balance
After 2025-03-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-11 · Grant · Acquired 758,400 · Balance 2,925,098 F1: 25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2017 Filed Sep 6, 2017 20:41 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 30,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-055891 · a4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 30,001 restricted stock units, all of which vested on September 2, 2017. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017. Read SEC document |
| August 22, 2017 Filed Aug 24, 2017 16:06 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 385,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001104659-17-053434 · a4.xml · derivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,110,000 Underlying: Common Stock · 385,000 shares Expires 2027-08-22 F1 · derivative.exercise_date: 48,125 vest immediately upon grant and 48,125 vest quarterly for 7 quarters following the date of grant. Read SEC document |
| April 07, 2017 Filed Apr 10, 2017 16:04 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantRestricted Stock Units · Derivative | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-022532 · a4.xml · derivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,001 Underlying: Common Stock · 90,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F2 · derivative.exercise_date: The RSU shall vest on January 30, 2018 provided that the reporting person provides continuous service to Trovagene, Inc. F2 · derivative.expiration_date: The RSU shall vest on January 30, 2018 provided that the reporting person provides continuous service to Trovagene, Inc. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 17:01 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000632 · a4.xml · derivative · entry 5 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,001 Underlying: Common Stock · 75,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F6 · derivative.exercise_date: The RSUs shall vest in equal annual installments over 4 years. F6 · derivative.expiration_date: The RSUs shall vest in equal annual installments over 4 years. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 17:01 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantRestricted Stock Units · Derivative | 30,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000632 · a4.xml · derivative · entry 4 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,001 Underlying: Common Stock · 30,001 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F5 · derivative.exercise_date: The RSU shall vest on September 2, 2017 provided that the reporting person provides continuous service to Trovagene, Inc. F5 · derivative.expiration_date: The RSU shall vest on September 2, 2017 provided that the reporting person provides continuous service to Trovagene, Inc. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 17:01 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000632 · a4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On May 2, 2016, the reporting person was granted 50,000 restricted stock units, all of which vested on January 2, 2017. The common stock into which such vested restricted stock units converted on January 2, 2017 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On May 2, 2016, the reporting person was granted 50,000 restricted stock units, all of which vested on January 2, 2017. The common stock into which such vested restricted stock units converted on January 2, 2017 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 17:01 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Tax withholdingCommon Stock | 23,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000632 · a4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,032 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 23,968 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2017. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 17:01 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000632 · a4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On May 2, 2016, the reporting person was granted 50,000 restricted stock units, all of which vested on January 2, 2017. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on May 4, 2016. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 17:00 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | PurchaseCommon Stock | 5,000 | $2.08 | $10,375.00 |
DisclosureSEC source: 0001104659-16-162330 · a4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.